Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics 2009. CA Cancer J Clin. 2009, 59: 225-249. 10.3322/caac.20006.
Article
Google Scholar
Hansen HH: Treatment of advanced non-small cell lung cancer. BMJ. 2002, 325: 452-453. 10.1136/bmj.325.7362.452.
Article
Google Scholar
Yang P, Allen MS, Aubry MC, Wampfler JA, Marks RS, Edell ES, Thibodeau S, Adjei AA, Jett J, Deschamps C: Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest. 2005, 128: 452-462. 10.1378/chest.128.1.452.
Article
Google Scholar
Ihde DC: Chemotherapy of lung cancer. N Engl J Med. 1992, 327: 1434-1441.
Article
CAS
Google Scholar
Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S, Olak J, Stover D, Strawn JR, Turrisi AT, Somerfield MR, American Society of Clinical Oncology: American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2004, 22: 330-353. 10.1200/JCO.2004.09.053.
Article
Google Scholar
Felip E, Stahel RA, Pavlidis N, ESMO Guidelines Task Force: ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC). Ann Oncol. 2005, 16: i28-29. 10.1093/annonc/mdi821.
Article
Google Scholar
Stinchcombe TE, Socinski MA: Treatment paradigms for advanced stage non-small cell lung cancer in the era of multiple lines of therapy. J Thorac Oncol. 2009, 4: 243-250. 10.1097/JTO.0b013e31819516a6.
Article
Google Scholar
Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH, Eastern Cooperative Oncology Group: Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med. 2002, 346: 92-98. 10.1056/NEJMoa011954.
Article
CAS
Google Scholar
Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008, 26: 3543-3551. 10.1200/JCO.2007.15.0375.
Article
CAS
Google Scholar
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L, National Cancer Institute of Canada Clinical Trials Group: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005, 353: 123-132. 10.1056/NEJMoa050753.
Article
CAS
Google Scholar
Pérez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabárbara P, Bonomi P: Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol. 2004, 22: 3238-3247. 10.1200/JCO.2004.11.057.
Article
Google Scholar
Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP, Baselga J: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol. 2003, 21: 2237-2246. 10.1200/JCO.2003.10.038.
Article
CAS
Google Scholar
Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003, 290: 2149-2158. 10.1001/jama.290.16.2149.
Article
CAS
Google Scholar
Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu CT, Ganul V, Roh JK, Bajetta E, O'Byrne K, de Marinis F, Eberhardt W, Goddemeier T, Emig M, Gatzemeier U, FLEX Study Team: Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009, 373: 1525-1531. 10.1016/S0140-6736(09)60569-9.
Article
CAS
Google Scholar
Carlsson J, Forssell Aronsson E, Hietala SO, Stigbrand T, Tennvall J: Tumour therapy with radionuclides: assessment of progress and problems. Radiother Oncol. 2003, 66: 107-117. 10.1016/S0167-8140(02)00374-2.
Article
CAS
Google Scholar
Fontanini G, De Laurentiis M, Vignati S: Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res. 1998, 4: 241-249.
CAS
Google Scholar
Rusch V, Baselga J, Cordon-Cardo C, Orazem J, Zaman M, Hoda S, McIntosh J, Kurie J, Dmitrovsky E: Differential expression of the epidermal growth factor receptor and its ligands in primary nonsmall cell lung cancers and adjacent benign lung. Cancer Res. 1993, 53: 2379-2385.
CAS
Google Scholar
Milas I, Komaki R, Hachiya T, Bubb R, Ro J, Langford L, Sawaya R, Putnam J, Allen P, Cox J, McDonnell T, Brock W, Hong W, Roth J, Milas L: Epidermal Growth Factor Receptor, Cyclooxygenase-2, and BAX Expression in the Primary Non-Small Cell Lung Cancer and Brain Metastases. Clinical Cancer Research. 2003, 9: 1070-1076.
CAS
Google Scholar
Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC: Pathology and Genetics of Tumors of the Lung, Pleura, Thymus and Heart. 2004, Lyon: IARC Press
Google Scholar
Sobin LH, Wittekind C: TNM Classification of Malignant Tumors. 2002, New York: Wiley-Liss
Google Scholar
Wei Q, Sheng L, Shui Y, Hu Q, Nordgren H, Carlsson J: EGFR, HER2, and HER3 expression in laryngeal primary tumors and corresponding metastases. Ann Surg Oncol. 2008, 15: 1193-1201. 10.1245/s10434-007-9771-3.
Article
Google Scholar
Shen L, Shui Y, Wang X, Sheng L, Yang Z, Xue D, Wei Q: EGFR and HER2 expression in primary cervical cancers and corresponding lymph node metastases: Implications for targeted radiotherapy. BMC Cancer. 2008, 8: 232-10.1186/1471-2407-8-232.
Article
Google Scholar
Wei Q, Chen L, Sheng L, Nordgen H, Wester K, Carlsson J: EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases. Int J Oncol. 2007, 31: 493-499.
Google Scholar
Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA, Varella-Garcia M: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005, 97: 643-655.
Article
CAS
Google Scholar
Hirsch FR, Varella-Garcia M, Bunn PA, Franklin WA, Dziadziuszko R, Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T, von Pawel J, Watkins C, Flannery A, Ellison G, Donald E, Knight L, Parums D, Botwood N, Holloway B: Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-smallcell lung cancer. J Clin Oncol. 2006, 24: 5034-5042. 10.1200/JCO.2006.06.3958.
Article
CAS
Google Scholar
Italiano A, Vandenbos FB, Otto J, Mouroux J, Fontaine D, Marcy PY, Cardot N, Thyss A, Pedeutour F: Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors. Ann Oncol. 2006, 17: 981-985. 10.1093/annonc/mdl038.
Article
CAS
Google Scholar
Gomez-Roca C, Raynaud CM, Penault-Llorca F, Mercier O, Commo F, Morat L, Sabatier L, Dartevelle P, Taranchon E, Besse B, Validire P, Italiano A, Soria JC: Differential Expression of Biomarkers in Primary Non-small Cell Lung Cancer and Metastatic Sites. J Thorac Oncol. 2009, 4: 1212-1220. 10.1097/JTO.0b013e3181b44321.
Article
Google Scholar
Badalian G, Barbai T, Rásó E, Derecskei K, Szendrôi M, Tímár J: Phenotype of Bone Metastases of Non-Small Cell Lung Cancer: Epidermal Growth Factor Receptor Expression and K-RAS Mutational Status. Pathol Oncol Res. 2007, 13: 99-104. 10.1007/BF02893484.
Article
CAS
Google Scholar